TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9619120
Drug: Curcumin 2
Normalized name: MICROCRYSTALLINE CELLULOSE 3 mg in 40 g / CURCUMIN 2 mg in 40 g CUTANEOUS CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 2 g/kg + Piperine 20 mg/kg in rats
Study: 9619120
Drug: Curcumin 2
Normalized name: MICROCRYSTALLINE CELLULOSE 3 mg in 40 g / CURCUMIN 2 mg in 40 g CUTANEOUS CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 2 g + Piperine 20 mg in humans
Study: 7862267
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (1 mg/kg body weight)
Study: 7862267
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (2 mg/kg body weight)
Study: 7862267
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (3 mg/kg body weight)
Study: 7862267
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (4 mg/kg body weight)
Study: 2919758
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 mg kg‐1)
Study: 2919758
Drug: Thiopental (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (4 mg kg‐1)
Study: 28653428
Drug: Dextroamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (10 mg daily for 3 weeks)
Study: 23715519
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention (supplementation with 1,200 mg n‐3 LCPUFAs per day and instructions to reduce arachidonic acid (AA) intake)
Study: 10714846
Drug: pethidine 17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: pethidine 17.5 mg
Study: 10714846
Drug: pentazocine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentazocine 7.5 mg
Study: 9175960
Drug: bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine with fentanyl 1 microgram ml‐1
Study: 9175960
Drug: bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine with fentanyl 2 micrograms ml‐1
Study: 9175960
Drug: bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine with fentanyl 3 micrograms ml‐1
Study: 9175960
Drug: bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine with fentanyl 4 micrograms ml‐1
Study: 1313120
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion at a rate of 30 ng.kg‐1.min‐1 during cardiopulmonary bypass (CPB)
Study: 1313120
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (Control group)
Study: 3886308
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg 3-times daily)
Study: 28419448
Drug: Match condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Match condition (tablet)
Study: 14738640
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no further treatment after endometrial resection)
Study: 9012304
Drug: Etomidate in
Normalized name: etomidate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate in lipid emulsion (0.51 mg/kg)
Study: 9012304
Drug: Propofol in
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol in long chain triglyceride emulsion (3.04 mg/kg)
Study: 3884690
Drug: Fluocortin butyl
Normalized name: fluocortin butyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butyl (FCB) 2 mg per day
Study: 3884690
Drug: Fluocortin butyl
Normalized name: fluocortin butyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butyl (FCB) 4 mg per day
Study: 3884690
Drug: Fluocortin butyl
Normalized name: fluocortin butyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butyl (FCB) 8 mg per day
Study: 31219949
Drug: Concentration-Controlled Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration-Controlled Dosing (CC) of EC-MPS
Study: 31219949
Drug: Fixed-Dosing (FD)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-Dosing (FD) of EC-MPS
Study: 28724273
Drug: Inhaled Salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Salbutamol (200 micrograms)
Study: 19228175
Drug: Lorazepam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4.5 mg/day
Study: 17973945
Drug: ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe (10 mg/day)
Study: 14985218
Drug: Zinc (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (10 mg as acetate, twice daily for 5 days)
Study: 14985218
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (10,000 microg retinol equivalents, twice daily for 4 days)
Study: 23949208
Drug: Collagen hydrolysate
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen hydrolysate (CH) 2.5 g
Study: 23949208
Drug: Collagen hydrolysate
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen hydrolysate (CH) 5.0 g
Study: 20564162
Drug: Paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (100 mg/m2 iv every 2 weeks)
Study: 20564162
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) (20 mg/m2 iv every 3 weeks)
Study: 16224085
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin sodium
Study: 10410403
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of dextran 40
Study: 10410403
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml of lactated Ringer's solution
Study: 1688835
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline crystalloid solution
Study: 1688835
Drug: Hetastarch colloid
Normalized name: Hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetastarch colloid solution
Study: 7064850
Drug: Acebutolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (100 mg)
Study: 22032759
Drug: Desvenlafaxine 25
Normalized name: DESVENLAFAXINE 25 mg ORAL TABLET, EXTENDED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 25 mg/d
Study: 22032759
Drug: Desvenlafaxine 50
Normalized name: desvenlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50 mg/d every other day
Study: 22032759
Drug: Desvenlafaxine 50/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50/25 mg/d
Study: 22032759
Drug: Desvenlafaxine 50
Normalized name: desvenlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50 mg/d - placebo
Study: 22032759
Drug: No taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: No taper
Study: 17230059
Drug: Duration and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration and type of chelation therapy
Study: 17230059
Drug: Age of
Normalized name: TITANIUM DIOXIDE 20 mg in 1 g TOPICAL STICK [Flormar Delicious Lip Stylo Sunscreen Broad Spectrum SPF 15 DS10 Collage of Citrus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age of beginning chelation therapy
Study: 12153824
Drug: Methylphenidate (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (moderate and high doses)
Study: 10201459
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg daily (maintenance)
Study: 10201459
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily (maintenance)
Study: 8519715
Drug: Fentanyl 15
Normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 15 micrograms with 80 mg hyperbaric lidocaine
Study: 8519715
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline with 80 mg hyperbaric lidocaine
Study: 2167110
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial embolization (TAE) using iodized oil (Lipiodol) mixed with anticancer agent (ACA)
Study: 2167110
Drug: Hepatic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic artery infusion (HAI) of anticancer agent (ACA)
Study: 2167110
Drug: Oral chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chemotherapy following TAE or HAI
Study: 206214
Drug: Surgical excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical excision of the tumor, chemotherapy, and radiation therapy as per study protocol
Study: 19666698
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with T4 (50 microg) and T3 (20 microg) for 12 weeks
Study: 19666698
Drug: T4 monotherapy
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 monotherapy for 12 weeks
Study: 1852141
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg bid orally)
Study: 7193603
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive 20/250 (EE/NG ratio 0.08)
Study: 7193603
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive 30/250 (EE/NG ratio 0.12)
Study: 7193603
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive 30/150 (EE/NG ratio 0.20)
Study: 7193603
Drug: Three-phase drug
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-phase drug (EE/NG ratio 0.35)
Study: 30702853
Drug: Real world
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real world data (RWD) studies on drug repurposing
Study: 17324009
Drug: Plerixafor plus
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor plus G-CSF
Study: 21392395
Drug: Oral diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diet and EN if necessary after 72 hours after hospital admission
Study: 19145396
Drug: Ibandronate (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (150 mg, once-monthly)
Study: 11490418
Drug: Doxicyclin 200
Normalized name: doxycycline hyclate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxicyclin 200 mg/day with nistatine for three weeks with 3‐week interval between the courses and bifidum‐bacterin administration between the courses and after the treatment
Study: 11490418
Drug: Biseptol 1920
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biseptol 1920 mg for 3 weeks then 960 mg 10 days a month
Study: 11490418
Drug: No antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibacterial drugs
Study: 9990420
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% solution
Study: 9990420
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% solution and Tretinoin 0.025% gel
Study: 24533510
Drug: Unopposed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed estrogen (estradiol valerate: 2 mg for 2 years)
Study: 23866906
Drug: Electroacupuncture (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (30 minutes with a mixed current of 2 Hz/120 Hz at 80% of bearable intensity) at 12 standard acupuncture points, twice per week for eight weeks (total of 16 sessions)
Study: 23866906
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no electroacupuncture treatment)
Study: 20593240
Drug: Rofecoxib (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (selective COX-2 inhibitor)
Study: 11168669
Drug: 0.3% gentian
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% gentian violet applied twice a day for nasal lesions (9 cases)
Study: 8779402
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml bupivacaine 0.25% + 0.1 mg fentanyl (B + F group)
Study: 8779402
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml bupivacaine 0.25% + 2 ml saline (BUP group)
Study: 29601997
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) restricted diet (<25:>50:25% daily calories from CHO: fat: protein)
Study: 29601997
Drug: Fat restricted
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat restricted diet (55:20:25% daily calories from CHO: fat: protein)
Study: 24641783
Drug: Powered rotating-oscillating
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powered rotating-oscillating toothbrush with repeated oral hygiene instructions (OHI) and motivation (Group E1)
Study: 24641783
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush with repeated oral hygiene instructions (OHI) and motivation (Group M1)
Study: 24641783
Drug: Powered rotating-oscillating
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powered rotating-oscillating toothbrush without repeated oral hygiene instructions (OHI) and motivation (Group E2)
Study: 24641783
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush without repeated oral hygiene instructions (OHI) and motivation (Group M2)
Study: 18284435
Drug: Troglitazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200 mg/day) for 12 weeks
Study: 10459816
Drug: Isepamicin 25
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 25 mg/kg on the first day followed by 15 mg/kg od for 4 days
Study: 10459816
Drug: Isepamicin 15
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 15 mg/kg od for 5 days
Study: 10459816
Drug: Isepamicin 15
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 15 mg/kg od for 10 days
Study: 10459816
Drug: Isepamicin dosing
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin dosing regimens
Study: 7541236
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg day‐1 for 7 days)
Study: 525840
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of a parasympatholytic agent
Study: 24313873
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (intravenous and oral) administered on two occasions
Study: 17427836
Drug: Statin therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy, specific dosage and duration not available
Study: 15899725
Drug: Tacrolimus capsules
Normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus capsules with sirolimus
Study: 11475731
Drug: Cassia angustifolia
Normalized name: Cassia angustifolia leaf
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cassia angustifolia extract (CAE) enema administration
Study: 155292
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide (IPTB) and disodium cromoglycate (DSCG)
Study: 155292
Drug: Fenoterol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (beta-adrenergic agonist)
Study: 26520171
Drug: Topical polyvinyl
Normalized name: Polyvinyl Alcohol
DrugBank: Polyvinyl alcohol (DB11060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical polyvinyl alcohol (PA)
Study: 22488578
Drug: ICG-augmented diode
Normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-augmented diode laser therapy (808 nm) with ICG (2 mg/kg body weight) and diode laser pulses (50-110 J/cm²)
Study: 22488578
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser therapy without ICG
Study: 11054990
Drug: Vitamin C;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C; specific dosage and duration not mentioned
Study: 8790030
Drug: Special Intervention
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special Intervention (SI) - dietary recommendations, antihypertensive drugs, counseling for smoking cessation
Study: 6360750
Drug: Fenoprofen 600
Normalized name: fenoprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen 600 mg, four times daily
Study: 6360750
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg, four times daily
Study: 6360750
Drug: Fenoprofen 600
Normalized name: fenoprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen 600 mg, four times daily (combined data from Weeks 1 and 2)
Study: 6360750
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg, four times daily (combined data from Weeks 1 and 2)
Study: 26654956
Drug: Client-centred activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centred activities in daily living intervention (CADL)
Study: 25972101
Drug: Cefazolin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (single intravenous dose)
Study: 23217479
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of pre-operative antibiotics (cefuroxime sodium and metronidazole)
Study: 23217479
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics (same antibiotics as group A)
Study: 23217479
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of pre-operative antibiotics (cefuroxime and metronidazole)
Study: 20652627
Drug: Dronedarone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone (400 mg or 800 mg once daily or 600 mg twice daily)
Study: 18520806
Drug: Weekly intravenous
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intravenous cetuximab (initial dose 400mg/m2; maintenance dose 250 mg/m2) with concomitant radiotherapy (64Gy/32 fractions/45 days)
Study: 2246493
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg twice daily
Study: 6286734
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril (5 or 10 mg) and hydrochlorothiazide (50 mg)
Study: 6286734
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 or 10 mg)
Study: 25130995
Drug: STAS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAS plus zoledronic acid (4 mg every 3 months for 18 months, intravenously)
Study: 22895556
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine plus aclacinomycin/cytarabine (DAA)
Study: 16143730
Drug: Ketamine (0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.23 mg/kg IV followed by 0.5 mg/kg infusion)
Study: 16143730
Drug: Amphetamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (0.25 mg/kg infusion)
Study: 12355581
Drug: Glucophage (Lipha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucophage (Lipha Pharmaceutical Industries, France)
Study: 10418540
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride 50 mg (cycle 1)
Study: 10418540
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride 100 mg (cycle 2)
Study: 2153765
Drug: CAV-HEM chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV-HEM chemotherapy
Study: 2153765
Drug: CAV chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV chemotherapy
Study: 2153765
Drug: CAV maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV maintenance therapy
Study: 2153765
Drug: CAV-HEM with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV-HEM with no maintenance therapy
Study: 28737452
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation program (1-hour sessions weekly for 8 weeks)
Study: 28737452
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (relaxation techniques weekly)
Study: 25015615
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (0.4 mg tamsulosin)
Study: 25015615
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (0.4 mg tamsulosin + 10 mg alfuzosin)
Study: 22441634
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200μg once daily
Study: 31821491
Drug: Oral education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral education
Study: 18671885
Drug: Oxpentifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxpentifylline (400 mg daily)
Study: 18671885
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet daily)